MolnuFIP™ delivers pure EIDD-1931, the active antiviral metabolite of molnupiravir, in a formulation designed exclusively for feline physiology. By using EIDD-1931 directly—rather than modifying human molnupiravir capsules—MolnuFIP™ provides a more precise, consistent, and veterinary-appropriate approach to FIP care.
Purpose-Built Feline Formulation
Each MolnuFIP™ capsule contains 15 mg of EIDD-1931, equivalent in activity to approximately 66 mg of molnupiravir (EIDD-2801).
This formulation is optimized for:
Feline metabolic rate
Gastrointestinal absorption profile
Reliable dose–response performance
The result is accurate, predictable antiviral activity with reduced variability compared to human-intended products.
Proven Antiviral Potency
Published research demonstrates that:
EIDD-1931 exhibits up to 10× greater in-vitro antiviral potency compared with molnupiravir (EIDD-2801).
EIDD-1931 demonstrates 7.3× higher potency than GS-441524 under similar test conditions.
This potency advantage enables therapeutic efficacy at lower milligram doses, supporting improved tolerability and rapid clinical response.
Reference:
Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity Against Enterovirus Infections In Vitro and In Vivo
https://www.mdpi.com/1999-4915/14/6/1142
Comprehensive Support Across FIP Presentations
MolnuFIP™ is formulated to support recovery across all major forms of FIP, including:
Wet FIP (effusive)
Dry FIP (non-effusive)
Mixed or transitional presentations
Additional formulation benefits:
Optimized for feline metabolism and tissue penetration
Highly consistent blood-level performance
Designed to support low relapse incidence when used according to veterinary guidance
Precision, Safety & Confidence in Every Dose
With MolnuFIP™, your cat receives an advanced, veterinary-engineered antiviral designed for dependable performance:
Scientifically grounded formulation
Consistent mg-per-kg dosing
No need to modify human medications
Backed by modern antiviral research
Visit molnufip.com for more information
EIDD-1931 Oral Capsules
Dosage Instructions
Administer one (1) capsule per 2.5 kg of body weight, given every 12 hours.
Dosing Examples
• Example 1: A 2.0 kg kitten diagnosed with the effusive (wet) form of FIP should receive one capsule every 12 hours.
• Example 2: A 4.6 kg adult cat diagnosed with the non-effusive (dry) form of FIP should receive two capsules every 12 hours.
Monitoring and Follow-Up
We strongly recommend that your cat receives a complete blood panel approximately every 30 days, in conjunction with ongoing evaluation by your primary veterinarian. Regular monitoring allows your veterinarian to assess clinical response and determine whether continued treatment, dose adjustment, or discontinuation is appropriate.